Navigation Links
Jubilant Enters Research Collaboration With AstraZeneca
Date:5/5/2009

NOIDA, India, May 5 /PRNewswire/ --

- Research Collaboration to Provide AstraZeneca With New Preclinical Drug Candidates

Jubilant Organosys Ltd, headquartered in India, announced today that its Bangalore, India, based subsidiary,Jubilant Biosys Ltd, has signed a research collaboration agreement with, AstraZeneca, and focused on delivering novel drug candidates into the international pharmaceutical company's pre-clinical pipeline. Under the shared risk-reward collaboration, which will initially focus on the neuroscience area, Jubilant aims to deliver a steady stream of discovery programs to AstraZeneca.

AstraZeneca will own the compounds developed under the collaboration with worldwide development and commercialization rights. Jubilant will be eligible to receive research funding spanning an initial five-year period. In addition, AstraZeneca will also pay Jubilant success-based development milestones, as well as royalties based on successful global commercialization of any of the compounds.

Commenting on this Collaboration, Mr. Shyam S Bhartia, Chairman & Managing Director and

Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Organosys Ltd, said: "We are very pleased to partner with AstraZeneca, this collaboration will leverage the innovative capabilities of AstraZeneca and Jubilant Biosys in providing a robust global drug discovery model. Through this partnership, Jubilant is confident of contributing to AstraZeneca's preclinical portfolio and anticipates significant rewards from successful downstream milestones. This partnership furthers Jubilant's strategy to be India's largest provider of innovative and integrated pharmaceutical solutions, enabling the global pharmaceutical industry's quest to discover affordable innovative medicines."

Jan Lundberg, Executive Vice-President, Global Discovery, at AstraZeneca says, "This collaboration complements our internal capabilities and increases the capacity of our pre-clinical programs. It is a concrete example of the innovative approaches we are taking to deliver a sustainable Discovery pipeline with a lean and agile organization. Ultimately, this will provide us with more shots on goal as we look to sustain a competitive portfolio and provide meaningful medicines to patients."

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: http://www.astrazeneca.com

About Jubilant Biosys

Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd.,provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 300 scientists specializing in multiple disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

For more information please visit: http://www.jubilantbiosys.com

About Jubilant Organosys

Jubilant Organosys Ltd. is an integrated pharmaceutical industry player, one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development services companies out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products ,exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to 150 customers across more than 50 countries around the world.For more information please visit: http://www.jubl.com

Disclaimer:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

    For further information contact:

    For Media:
    Seema Ahuja
    Jubilant Organosys Limited
    Ph:     +91-120-4361062
    Mobile: +91-9810631779
    email:seema_ahuja@jubl.com

    For Business Queries: Europe and APAC:
    Saurabh Kapure
    Senior Manager Business Development
    Jubilant Biosys and Jubilant Chemsys Ltd.
    Direct: +91-80-6662-8852
    e-mail: saurabh_rk@jubilantbiosys.com

    For Investors:
    Deepak Malik
    Jubilant Organosys Limited
    Tel: +91-120-4361114
    Fax: +91-120-2516629
    E-mail: deepak_malik@jubl.com

    For Business Queries: USA
    Corey Jacklin
    Director, Business Development
    Jubilant Biosys
    Tel: +1-215-369-0965
    E-mail: Corey_Jacklin@jubilantbiosys.com


'/>"/>
SOURCE Jubilant Organosys Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
2. Elusys Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
3. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
4. Another LNA-based RNA Inhibitor Enters Clinical Trials
5. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
6. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
7. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
8. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
9. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
10. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
11. Pharmaleads Lead Candidate for Pain, PL37, Enters Phase I
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
Breaking Medicine Technology:
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... ... in the Orthodontics and Clear Aligner clinical and commercial support services market) has ... of Dentistry (PGSD) in Sydney, Australia. , The PGSD is the first ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... In just ... Brain Booster has already been receiving positive feedback from customers trying the product for ... , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... , ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A ... is the creation of published author, Bill Miller. Bill Miller has a ... more than a decade of addiction to prescription drugs. He has a ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “Psalms of Humidity”: ... peace of mind and move the readers one step closer to God. “Psalms of ... realized that his mistakes that have been made within his life are the very ...
Breaking Medicine News(10 mins):